Cardiex Ltd
ASX:CDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cardiex Ltd
Total Equity
Cardiex Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cardiex Ltd
ASX:CDX
|
Total Equity
AU$5.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Somnomed Ltd
ASX:SOM
|
Total Equity
AU$50m
|
CAGR 3-Years
26%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Cochlear Ltd
ASX:COH
|
Total Equity
AU$1.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
17%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Total Equity
AU$22m
|
CAGR 3-Years
64%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Total Equity
AU$58.8m
|
CAGR 3-Years
35%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Total Equity
AU$19.7m
|
CAGR 3-Years
36%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Cardiex Ltd
Glance View
CardieX Ltd. is engaged in the designing, manufacturing, and marketing of medical devices for use in cardiovascular health management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm is focused on designing, manufacturing and marketing medical devices for use in cardiovascular health management. The company operates through its subsidiaries, including ATCOR and CONNEQT. The firm's ATCOR division provides medical devices for measuring arterial stiffness and central blood pressure waveforms based on its FDA-cleared and patented SphygmoCor technology. Under the ATCOR.X brand, the Company also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. The firm's digital platform, ArtyNet, is a connected software as a service ecosystem providing physicians with a telehealth solution for remotely managing patients' health. CONNEQT develops and markets consumer wearable and home health devices focused on heart health and its patented fitness and wellness parameters.
See Also
What is Cardiex Ltd's Total Equity?
Total Equity
5.6m
AUD
Based on the financial report for Jun 30, 2025, Cardiex Ltd's Total Equity amounts to 5.6m AUD.
What is Cardiex Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
3%
Over the last year, the Total Equity growth was 37%. The average annual Total Equity growth rates for Cardiex Ltd have been -5% over the past three years , -1% over the past five years , and 3% over the past ten years .
